Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.50
by Amy Steele · The Cerbat GemGain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.50.
A number of brokerages have recently issued reports on GANX. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a report on Friday. Finally, Roth Mkm reiterated a “buy” rating and issued a $10.00 price target on shares of Gain Therapeutics in a report on Friday, December 19th.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in shares of Gain Therapeutics in the 4th quarter valued at $45,000. Engineers Gate Manager LP purchased a new position in shares of Gain Therapeutics in the 4th quarter valued at $47,000. OMERS ADMINISTRATION Corp purchased a new position in Gain Therapeutics during the 4th quarter worth $120,000. Marshall Wace LLP grew its stake in Gain Therapeutics by 849.3% during the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after buying an additional 1,487,186 shares during the last quarter. Finally, State Street Corp grew its stake in Gain Therapeutics by 72.9% during the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock worth $507,000 after buying an additional 66,400 shares during the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.
Gain Therapeutics Trading Up 1.1%
Shares of NASDAQ GANX opened at $1.89 on Friday. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $2.11 and a two-hundred day simple moving average of $2.39. The firm has a market cap of $79.83 million, a PE ratio of -3.10 and a beta of 0.11. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34.
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. Analysts expect that Gain Therapeutics will post -1 earnings per share for the current fiscal year.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.
Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.